| 产品描述： | SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 |
| 靶点： |
G protein-coupled Bile Acid Receptor 1;GPCR19 |
| 体外研究： |
SBI-115 (100-200 µM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes. Cell Proliferation Assay Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100, 200 µM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. |
| 参考文献： |
1. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.934 ml |
14.672 ml |
29.344 ml |
| 5 mM |
0.587 ml |
2.934 ml |
5.869 ml |
| 10 mM |
0.293 ml |
1.467 ml |
2.934 ml |
| 50 mM |
0.059 ml |
0.293 ml |
0.587 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京